reports
Appendix 4C – Q3 FY24 Quarterly Cash Flow Report
Appendix 4C – Q3 FY24 Quarterly Cash Flow Report Highlights ATH434-201 Phase 2 baseline data confirm approach to target biomarkers for slowing disease progressionPresented promising nonclinical data on ATH434 in a primate model of Parkinson’s diseaseRaised approximately A$5.25M to strengthen the balance sheetReceived an A$3.9M Research and Development Tax Incentive RefundCash balance on 31 March 2024 of A$18.3M MELBOURNE, Australia and SAN FRANCISCO, April 30, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company d...
- ABGSC IT Research
- Daniel Thorsson
- Simon Granath
Macerich Reports First Quarter 2024 Results
Macerich Reports First Quarter 2024 Results SANTA MONICA, Calif., April 30, 2024 (GLOBE NEWSWIRE) -- The Macerich Company (NYSE: MAC) has released its First Quarter 2024 Earnings Results and Supplemental Information by posting it to the Investor Relations section of its website at . As previously announced, management will hold a conference call at 10:00 a.m. Pacific Time (1:00 p.m. Eastern Time) today, Tuesday, April 30, 2024, to discuss quarterly results. Participants who wish to join the conference by telephone must register at the dial-in registration link below to receive the dial-i...
Duratec Limited: 2 directors
Two Directors at Duratec Limited bought 44,000 shares at between 1.050AUD and 1.050AUD. The significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the ...
Eniro Group AB: 1 director
A director at Eniro Group AB sold 115,000,000 shares at 0.900SEK and the significance rating of the trade was 86/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clea...
NanoXplore annonce la clôture d'une nouvelle facilité de crédit de 60 ...
NanoXplore annonce la clôture d'une nouvelle facilité de crédit de 60 millions de dollars et fait une mise à jour de son plan stratégique quinquennal MONTRÉAL, 30 avr. 2024 (GLOBE NEWSWIRE) -- NanoXplore Inc. ("NanoXplore" ou la "Société") (TSX : GRA et OTCQX : NNXPF), une entreprise de graphène de renommée mondiale, annonce la clôture d'une nouvelle facilité de crédit pour ses filiales opérationnelles avec la Banque Royale du Canada (« RBC »). En vertu de l'accord, la RBC fournira aux filiales de NanoXplore jusqu'à 60 millions de dollars canadiens. La facilité de crédit, qui regroupe ma...
U.S. Energy Corp. Announces Its Participation in the EF Hutton Annual ...
U.S. Energy Corp. Announces Its Participation in the EF Hutton Annual Global Conference HOUSTON, April 30, 2024 (GLOBE NEWSWIRE) -- U.S. Energy Corp (NASDAQ: USEG, “U.S. Energy” or the “Company”), a growth-focused energy company engaged in operating a portfolio of high-quality producing oil and natural gas assets, announced today that it will be participating in the EF Hutton Global Conference on May 15, 2024, at the Plaza Hotel in New York City. Ryan Smith, Chief Executive Officer of the Company, will host one-on-one meetings with investors at the conference. U.S. Energy is available ...
NanoXplore Announces Closing of $60M New Credit Facility and Provides ...
NanoXplore Announces Closing of $60M New Credit Facility and Provides Update on The Financing of Its 5-year Strategic Plan MONTREAL, April 30, 2024 (GLOBE NEWSWIRE) -- NanoXplore Inc. ("NanoXplore" or the "Corporation") (TSX: GRA and OTCQX: NNXPF), a world-leading graphene company, announces the closing of a new credit facility with the Royal Bank of Canada (“RBC”). Under the agreement, RBC will provide NanoXplore’s subsidiaries with up to $60M CAD. The credit facility, inclusive of an existing equipment lease and other financial products, will provide a $10M revolving credit line, u...
- Soomit Datta
AMX(Buy, TP: $24, +24%) Televisa (Neutral, $3.5, +11%) Megacable (Neut...
The market continued to eek out broadband growth in Q1, with Megacable leading the charge. We applaud management’s execution here and the double digit revenue and EBITDA growth, though this now seems embedded in expectations; we think it’s time to close out Megacable stock gains (30% YTD), trading on a 5.5% EFCF yield for 2025. Our target remains MXN55, though we have taken out the probability of cable-cable deal synergies, offset by upgrades following Q1s.
Believe S A: 1 director
A director at Believe S A sold 11,684,314 shares at 15.000EUR and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearl...
SOPHiA GENETICS to Present at the 2024 RBC Capital Markets Global Heal...
SOPHiA GENETICS to Present at the 2024 RBC Capital Markets Global Healthcare Conference BOSTON and ROLLE, Switzerland, April 30, 2024 (GLOBE NEWSWIRE) -- SOPHiA GENETICS, a cloud-native software company and a leader in data-driven medicine, today announced that Chief Financial Officer and Chief Operating Officer, Ross Muken, will present at the 2024 RBC Capital Markets Global Healthcare Conference in New York City on Tuesday, May 14, 2024, at 3:35 p.m. EDT. The presentation will be webcast live on the . Additionally, a replay will be available on the website after its completion. About ...
Harmony Biosciences Reports Strong First Quarter Financial Results and...
Harmony Biosciences Reports Strong First Quarter Financial Results and Acceleration of Its Growth Strategy; Advances Pitolisant Franchise to Extend Revenue Potential Beyond 2040; Strenghtens Sleep/Wake Leadership and Diversifies Into Rare Epilepsy WAKIX® (pitolisant) Net Revenue of $154.6 Million for First Quarter 2024; ~30% Growth Year-over-Year Supplemental New Drug Application for Pitolisant in Idiopathic Hypersomnia Planned for Second Half 2024 On Track Toward Pediatric Exclusivity to Extend WAKIX Exclusivity to September 2030: Pediatric Narcolepsy sNDA PDUFA Date of June 21, 2024; PW...
Clearside Biomedical to Report First Quarter 2024 Financial Results an...
Clearside Biomedical to Report First Quarter 2024 Financial Results and Provide Corporate Update on Thursday, May 9, 2024 ALPHARETTA, Ga., April 30, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that its first quarter 2024 financial results will be reported on Thursday, May 9, 2024 after the close of the financial markets. Management will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss the result...
Inari Amertron Bhd: 1 director
A director at Inari Amertron Bhd sold 2,000,000 shares at 0.000MYR and the significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cl...
Newron Announces Positive Top-line Results From Potentially Pivotal Ph...
MILAN--(BUSINESS WIRE)-- Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system (CNS), today announced positive top-line results from its potentially pivotal study 008A, evaluating the safety, tolerability and efficacy of evenamide (30 mg bid) in patients with chronic schizophrenia currently being treated with a second-generation antipsychotic including clozapine, but demonstrating an inadequate response to that treatment. The study met it...
Skye Bioscience to Present Two Posters at Association for Research in ...
Skye Bioscience to Present Two Posters at Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting SAN DIEGO, April 30, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel classes of therapeutic drugs that modulate the endocannabinoid system, today announced that it will present two posters at the Association for Research in Vision and Ophthalmology (ARVO) 2024 Annual Meeting being held May 5-9, 2024, in Seattle, Washington. Details of the...
Solaris Announces Award of Option to Acquire Key Concessions Hosting P...
Solaris Announces Award of Option to Acquire Key Concessions Hosting Porphyry Copper and Epithermal Gold Potential Adjacent to Warintza VANCOUVER, British Columbia, April 30, 2024 (GLOBE NEWSWIRE) -- Solaris Resources Inc. (TSX: SLS; NYSE: SLSR) (“Solaris” or the “Company”) is pleased to announce that the Ecuadorian state-owned mining company, Empresa Nacional Minera (“ENAMI EP”), has awarded the Company an option to acquire up to a 100% interest in 10 new explorations concessions. These concessions comprise a land package of ~40,000 hectares adjacent to the Warintza Project (“Warintza” o...
ASLAN Pharmaceuticals to Host KOL Panel Discussion on Treatment Option...
ASLAN Pharmaceuticals to Host KOL Panel Discussion on Treatment Options for Atopic Dermatitis Patients With an Inadequate Response to Dupilumab ASLAN management will present new data from the interim analysis of the TREK-DX studyRegister to attend the webinar event on May 7, 2024 at 8:00 AM ET SAN MATEO, Calif. and SINGAPORE, April 30, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that it will host a virtual Key Opinio...
Capital Product Partners L.P. Announces First Quarter 2024 Financial R...
Capital Product Partners L.P. Announces First Quarter 2024 Financial Results ATHENS, Greece, April 30, 2024 (GLOBE NEWSWIRE) -- Capital Product Partners L.P. (the “Partnership”, “CPLP” or “we” / “us”) (NASDAQ: CPLP), an international owner of ocean-going vessels, today released its financial results for the first quarter ended March 31, 2024. Highlights Three-month periods ended March 31, 20242023Increase / (Decrease)Revenues$104.5 million$81.0 million29%Expenses$54.9 million$45.1 million22%Interest expense and finance cost$34.0 million$23.7 million43%Net Income$33.9 million$10.0 millio...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.